Live
- Harish Rao challenges Congress govt. to implement loan waiver by August 15
- German far-right's top EU candidate to carry on despite aide's arrest
- Metal, PSU stocks lead market gains
- Congress ready to set 'dangerous precedent' by implementing Inheritance Tax: PM Modi
- Countdown starts for polling for 14 LS seats in K'taka, public campaigning to end today
- Where are the two crore jobs that were promised, asks Congress chief Kharge as Kerala prepares to vote
- Ericsson, IIT Kanpur's tech incubator F.I.R.S.T to drive financial solution innovations
- WhatsApp Update: Admins Can Soon Hide Specific Groups From Comunity List
- Massive Rally Held in Southern Constituency as Jana Sena, TDP and BJP Unite for Election Campaign
- Former MLA Gouru Charitha Reddy Holds Road Show and Meeting Program Ahead of General Elections
DRL to defend against price fixing conspiracy allegation
The company said it was among the 21 generic pharmaceutical companies and 15 other individual defendants
New Delhi: Drug maker Dr Reddy's on Tuesday said it will 'vigorously defend' against allegations that it engaged in conspiracy to fix prices in the US.
In a regulatory filing, the company said it was among the 21 generic pharmaceutical companies and 15 other individual defendants against whom 49 US states, the Commonwealth of Puerto Rico and the District of Columbia had filed a complaint in the US District Court for the District of Connecticut with respect to 116 generic drugs.
"The complaint alleges that Dr Reddy's US subsidiary and the other named defendants engaged in a conspiracy to fix prices and to allocate bids and customers in the United States in the sale of the drugs," the company said.
Reacting to the lawsuit, Dr Reddy's said, "We intend to vigorously defend against these allegations and are in the process of filing our response with the District Court of Connecticut."
It further said, "Currently, we do not foresee any material impact to our operations and consolidated results with respect to this matter."
The company said its US subsidiary is specifically named as a defendant with respect to five generic drugs (Ciprofloxacin HCL tablets, Glimepiride tablets, Oxaprozin tablets, Paricalcitol and Tizanidine), for an alleged "overarching conspiracy."
